A5003176851- Treatment of Major Depression
- Dermatology and Skin Diseases
- Allergic Rhinitis and Sensitization
- Food Allergy and Anaphylaxis Research
- Stress Responses and Cortisol
- Neurotransmitter Receptor Influence on Behavior
- Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Intensive Care Unit Cognitive Disorders
- Anesthesia and Sedative Agents
- Functional Brain Connectivity Studies
- Chemical synthesis and alkaloids
- Receptor Mechanisms and Signaling
- Anesthesia and Neurotoxicity Research
- Psychedelics and Drug Studies
- Neuroendocrine regulation and behavior
- Antibiotics Pharmacokinetics and Efficacy
- Urticaria and Related Conditions
- Obstructive Sleep Apnea Research
- Pharmaceutical studies and practices
- Neuroscience and Neuropharmacology Research
- Perfectionism, Procrastination, Anxiety Studies
- Attention Deficit Hyperactivity Disorder
- Epilepsy research and treatment
Leo Pharma (Denmark)
2020-2022
Lundbeck (Denmark)
2002-2019
Tralokinumab is a fully human monoclonal antibody that specifically neutralizes interleukin-13, key driver of atopic dermatitis (AD).To evaluate the efficacy and safety tralokinumab in combination with topical corticosteroids (TCS) patients moderate-to-severe AD who were candidates for systemic therapy.This was double-blind, placebo plus TCS controlled phase III trial. Patients randomized 2 : 1 to subcutaneous 300 mg or every weeks (Q2W) as needed over 16 weeks. achieved an Investigator's...
Tralokinumab, a fully human IgG4 monoclonal antibody that specifically binds with high affinity to interleukin‐13, effectively reduces moderate‐to‐severe atopic dermatitis (AD) when given every 2 weeks. The incidence of conjunctivitis is elevated vs. placebo, but severity and aetiology have not been examined. To analyse data recorded in five randomized, placebo‐controlled trials tralokinumab adult patients AD. Overall, 2285 adults AD were studied up 16 Cochran–Mantel–Haenszel weights applied...
Abstract Background Tralokinumab is a fully human monoclonal antibody that neutralizes the activity of interleukin-13, key pathogenic driver atopic dermatitis (AD). Clinical trials including adults with moderate-to-severe AD, up to 52 weeks’ duration, showed tralokinumab was efficacious and well tolerated. Objectives To characterize safety profile for treatment AD. Methods Safety laboratory measures were assessed in pooled analyses phase II III placebo-controlled clinical AD (NCT02347176,...
Cognitive dysfunction is common in depression during both acute episodes and remission. Vortioxetine a novel multimodal antidepressant that has improved cognitive function including executive depressed patients randomised placebo-controlled clinical trials. However, it unclear whether vortioxetine able to target directly the neural circuitry implicated deficits depression. Remitted (n=48) healthy volunteers were receive 14 days treatment with 20 mg or placebo double-blind design. The effects...
Residual cognitive symptoms in major depressive disorder (MDD) are common, yet poorly investigated. We explored the effectiveness of vortioxetine as adjunctive treatment to selective serotonin reuptake inhibitors (SSRI) and monotherapy versus continued SSRI, patients with MDD who achieved full or partial remission but report residual symptoms. Patients (18–65 years old, N =151) diagnosed MDD, a Hamilton Depression Rating Scale 17-items total score ≤10 Perceived Deficits...
Tonic immobility (TI) is considered to be an innate fear response characterized by a temporary state of profound and reversible motor inhibition. TI occurs in wide range species predator–prey confrontation hypothesized terminal defence occurring when there physical contact between prey predator. The objective the present study was investigate validity model guinea pigs for detection anxiolytic and/or antidepressant drug activity. Compounds that reduced include serotonin (5-HT) releaser...
Psychopharmacology, H. Lundbeck A/S, Valby, Copenhagen, Denmark E-mail: [email protected] Abstracts of the 11th Biennial EBPS Meeting